Company / Return on Equity (ROE)
NovaBay Pharmaceuticals, Inc. Return on Equity (ROE) History
FY2016-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-290.9%
FY2023
5-year range
-290.9% / -57.3%
FY2019-FY2023
Trend
-189.4%
vs FY2022
Sector context
#187 of 190
Health Care
What the data says
NovaBay Pharmaceuticals, Inc. reports negative total equity of -290.9% in FY2023. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-290.9% in FY2023 with a 5-year CAGR of -158.8%.
Declined from -57.3% to -290.9% over the past 2 years.
Health Care sector context is included.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -201.3pp
- 5-Year Change
- -158.8pp
- 10-Year Change
- -
Sector benchmark
Bottom 2% in Health CareTop 98% of 190This company -290.9% Sector average -50.3%
▼
-478.2% below sector average
Key checks
Key Insights
- In FY2023, return on equity (roe) decreased 189.4% year-over-year.
- Currently 240.6pp below the Health Care sector average.
- Peak return on equity (roe) was recorded in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -5.51 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2024 | - | - |
| FY2023 | -290.9% | -189.4% |
| FY2022 | -100.5% | -75.5% |
| FY2021 | -57.3% | +36.1% |
| FY2020 | -89.6% | - |
| FY2019 | - | - |
| FY2018 | -132.1% | +53.7% |
| FY2017 | -285.4% | -54.1% |
| FY2016 | -185.2% | - |
| FY2015 | - | - |
As of FY2023 · SEC 10-K · Updated Feb 28, 2026